| 6/7/2022 |
Metabolon Expands Data Access Strategy to Include TwinsUK Registry |
PR Newswire |
New collaboration between Metabolon and King's College London to analyze TwinsUK clinical data , gain insights into the interplay between the gut microbial community and human health, and expand disease coverageMORRISVILLE, N.C. Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, announces a partnership with King's College London to perform metabolomics analysis on TwinsUK registry samples as part of Metabolon's data access strategy ... |
| 6/6/2022 |
Polypid (PYPD) PolyPid Announces Presentation of D-PLEX‚ÇÅ‚ÇÄ‚ÇÄ Phase 2 Clinical Data at ASM Microbe 2022 |
researchpool.com |
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentationPETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today ... |
| 6/6/2022 |
Jacobio Announces Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at 2022 ASCO Annual Meeting | Business & Finance | citizentribune.com |
citizentribune.com |
BEIJING and SHANGHAI and BOSTON, June 5, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced the phase I clinical data of KRAS G12C inhibitor JAB-21822 at the 2022 annual meeting of American Society of Clinical Oncology (ASCO).As of April 1, 2022, the Phase I clinical data of non-small cell lung cancer patients with KRAS G12C mutation shows that the overall response rate (ORR) is 56.3% (18/32) and the ... |
| 6/6/2022 |
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases |
PR Newswire |
Presentation marks first clinical data set with a KRAS G12C -inhibitor in patients with active, untreated CNS metastases SAN DIEGO Mirati Therapeutics, Inc. (NASDAQ: MRTX ), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRAS G12C -mutated non-small cell lung cancer (NSCLC) with active and untreated central ... |
| 6/6/2022 |
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting |
Business Wire |
... or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, 2022. The presentation outlines a summary of clinical data as of a May 31, 2022, data-cut date.“Adicet is a pioneer in the field of gamma delta CAR T cell therapies and it is gratifying to see the highly encouraging clinical data ... |
| 6/6/2022 |
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics‚Ñ¢ therapeutic cancer vaccine for glioblastoma, at ASCO 2022 |
PR Newswire |
... June 6, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform , today announces proof-of-concept immune response data and first clinical data from its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo®) +/- an anti-VEGF therapy (bevacizumab, Avastin®), for the treatment of patients with first progression/recurrence ... |
| 6/6/2022 |
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics‚Ñ¢ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022 |
PR Newswire |
... June 6, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform , today announces proof-of-concept immune response data and first clinical data from its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo®) in patients with non-resectable adrenocortical carcinomas (ACC), treated with at least one line (but not ... |
| 6/5/2022 |
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting |
PR Newswire |
... Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data of IBI110 (anti-LAG-3 monoclonal antibody) from three clinical trials will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2022 . This includes clinical data from ... |
| 6/5/2022 |
Jacobio Announces Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at 2022 ASCO Annual Meeting |
PR Newswire |
BEIJING and SHANGHAI and BOSTON Jacobio Pharma (1167.HK) announced the phase I clinical data of KRAS G12C inhibitor JAB-21822 at the 2022 annual meeting of American Society of Clinical Oncology (ASCO).As of April 1, 2022 , the Phase I clinical data of non-small cell lung cancer patients with KRAS G12C mutation shows that the overall response rate (ORR) is 56.3% (18/32) and the disease control rate (DCR ... |
| 6/4/2022 |
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 |
headlinesoftoday.com |
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 Press-Releases By Business Wire On Jun 5, SAN DIEGO & TOKYO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing ... |
| 6/4/2022 |
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 |
onenewspage.com |
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022Published PublishedSAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from ... |
| 6/4/2022 |
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel | Business Wire |
Business Wire |
... with other companies engaged in the weight loss industry; (iv) Gelesis’ ability to finance and complete successfully the commercial launch of Plenity® and its growth plans, including new possible indications and the clinical data from ongoing and future studies about liver and other diseases; (v) failure to realize the anticipated benefits of the business combination, including as a result of a delay or difficulty in integrating the businesses ... |
| 6/3/2022 |
Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting | Business Wire |
Business Wire |
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, today announced the presentation of new clinical data on BCA101, a bifunctional antibody designed to target the TGF-β trap to EGFR+ tumors. Data from the dose escalation phase of the ongoing Phase 1/1b trial of BCA101 as a monotherapy ... |
| 6/2/2022 |
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022 |
Yahoo News |
SUZHOU, China , June 1, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for the dose-escalation part of the Phase I study of TST001 in combination with CAPOX as the first line treatment of advanced and metastatic G/GEJ cancer has been published on the ASCO's website ... |
| 6/2/2022 |
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update |
PR Newswire |
... Further Development Activities in Ulcerative Colitis Without a Partner –– Focus to Remain on Ongoing Phase 3 Development of Vidofludimus Calcium in Multiple Sclerosis, and Ongoing IMU-935 and IMU-856 Programs with Clinical Data for Both Expected in 2022 –– $93.1 Million in Cash and Cash Equivalents as of May 31, 2022 Expected to Fund Immunic Into the Fourth Quarter of 2023 –– Conference Call and ... |
| 6/1/2022 |
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022 |
PR Newswire |
SUZHOU, China , June 1, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for the dose-escalation part of the Phase I study of TST001 in combination with CAPOX as the first line treatment of advanced and metastatic G/GEJ cancer has been published on the ASCO's website ... |
| 6/1/2022 |
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022 |
advfn.com |
SUZHOU, China , June 1, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for the dose-escalation part of the Phase I study of TST001 in combination with CAPOX as the first line treatment of advanced and metastatic G/GEJ cancer has been published on the ASCO's website ... |
| 5/31/2022 |
Zealand Pharma A/S (ZLDPF) Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide |
researchpool.com |
Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist DapiglutidePRESS RELEASE – NO. 1 / 2022Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide- A total of five presentations with Zealand Pharma products have been accepted ... |
| 5/31/2022 |
Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022 | Business Wire |
Business Wire |
ZUG, Switzerland--( BUSINESS WIRE )--Galderma will present a range of new clinical data and analyses across its portfolio during nine poster sessions and two symposia at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.“At Galderma, we are committed to advancing dermatology for every skin story. The extensive series of oral and poster presentations with new data from across our ... |
| 5/28/2022 |
How clinical data cbd oil adhd can Save You Time, Stress, and Money. |
mybjjblog.com |
How clinical data cbd oil adhd can Save You Time, Stress, and Money.Doctors are either afraid of remaining sued for problems prescribing pain meds, are they turn out not creating quite much funds prescribing meds.Having said that, in most cases, intensive medical research will need to get done right before a physician can prescribe CBD for OAB. Nevertheless, there are a lot of positive indications when it comes ... |